New titanium implant could let amputees ditch the socket
NCT ID NCT06636136
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a titanium implant called OPRA that connects a prosthetic leg directly to the shinbone, bypassing the need for a traditional socket. Researchers will follow 30 adults with below-knee amputations for up to 5 years after surgery to see if the implant improves function, reduces pain, and boosts quality of life. The goal is to offer a better option for people who have trouble using a socket prosthesis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- OPRA implant system (titanium implant surgically placed into the shinbone to attach a prosthetic leg directly to the bone)
- What this could lead to
- If successful, this could offer a more comfortable and functional alternative to traditional socket prostheses for people with below-knee amputations, potentially improving mobility and reducing skin problems.
- What could go wrong
- This is an early-stage study with only 30 participants, so results may not apply to everyone. Surgery carries risks like infection, implant failure, and the need for additional procedures.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMPUTATION; TRAUMATIC, LEG, LOWER are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Orthopaedic Surgery and Department of Anesthesiology & Critical Care Penn Medicine University City
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Orhopaedic Surgery Service, Walter Reed National Military Medical Center
RECRUITINGBethesda, Maryland, 20889, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.